Login to Your Account



Complix's Series B to Move Alphabodies into the Clinic

By Nuala Moran
Staff Writer

Tuesday, November 13, 2012
LONDON – Complix NV is in the thick of a €15 million to €20 million (US$19 million to $25 million) Series B fundraising, as it prepares to move the first of its intracellular-targeting Alphabodies into Phase I trials in 2013.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription